WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsNephros Inc (NEPH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 151223% more annual revenue ($28.43B vs $18.79M). NEPH leads profitability with a 6.4% profit margin vs 4.1%. NEPH trades at a lower P/E of 28.3x. MDLN earns a higher WallStSmart Score of 52/100 (C-).

MDLN

Buy

52

out of 100

Grade: C-

Growth: 6.0Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9

NEPH

Hold

40

out of 100

Grade: F

Growth: 6.7Profit: 5.0Value: 5.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.67

$24.25 discount

UndervaluedFair: $66.92Overvalued
NEPHSignificantly Overvalued (-438.7%)

Margin of Safety

-438.7%

Fair Value

$0.75

Current Price

$3.05

$2.30 premium

UndervaluedFair: $0.75Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN0 strengths · Avg: 0/10

No standout strengths identified

NEPH1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
22.2%8/10

Revenue surging 22.2% year-over-year

Areas to Watch

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.9x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

NEPH4 concerns · Avg: 3.3/10
P/E RatioValuation
28.3x4/10

Moderate valuation

Market CapQuality
$33.10M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
6.4%3/10

6.4% margin — thin

Operating MarginProfitability
0.4%3/10

Operating margin of 0.4%

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

Revenue growth of 14.8% demonstrates continued momentum.

Bull Case : NEPH

The strongest argument for NEPH centers on Revenue Growth. Revenue growth of 22.2% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Bear Case : NEPH

The primary concerns for NEPH are P/E Ratio, Market Cap, Profit Margin.

Key Dynamics to Monitor

MDLN profiles as a value stock while NEPH is a growth play — different risk/reward profiles.

NEPH is growing revenue faster at 22.2% — sustainability is the question.

NEPH generates stronger free cash flow (230,000), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (52/100 vs 40/100) and 14.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Nephros Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.

Want to dig deeper into these stocks?